The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
Name: GefitinibDescription: Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;Type: Other
Radiotherapy Combined With Gefitinib
Single Group Assignment
There is one SNP
Inclusion Criteria: - Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for surgery) or stage Ⅳ(only single-site single transfer ); - Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month; - Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation); - Patients must be informed of the investigational nature of the study and must sign an informed consent form; - Presence of at least one measurable/evaluable according to RECIST criteria. --- L858R ---